GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (OTCPK:OXBDF) » Definitions » Institutional Ownership

OXBDF (Oxford BioMedica) Institutional Ownership : 20.35% (As of Dec. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Oxford BioMedica Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oxford BioMedica's institutional ownership is 20.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oxford BioMedica's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oxford BioMedica's Float Percentage Of Total Shares Outstanding is 0.00%.


Oxford BioMedica Institutional Ownership Historical Data

The historical data trend for Oxford BioMedica's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Institutional Ownership Chart

Oxford BioMedica Historical Data

The historical data trend for Oxford BioMedica can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 23.66 21.25 21.62 22.59 21.85 22.07 21.62 21.40 21.03 21.01

Oxford BioMedica Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Oxford BioMedica Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.